+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuropeptide Y Receptor"

Neuropeptide Y Receptor Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Neuropeptide Y Receptor Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • July 2023
  • 73 Pages
  • Global
From
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • May 2022
  • 35 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Neuropeptide Y Receptor (NPY-R) is a G-protein coupled receptor (GPCR) that is involved in the regulation of a variety of physiological processes in the central nervous system (CNS). It is a target for the development of drugs for the treatment of CNS disorders such as anxiety, depression, and addiction. NPY-R agonists have been shown to have anxiolytic and antidepressant effects, while antagonists have been shown to reduce drug-seeking behavior. NPY-R is a promising target for the development of CNS drugs, and several companies are actively researching and developing drugs targeting this receptor. These include AbbVie, AstraZeneca, Eli Lilly, Merck, and Pfizer. Show Less Read more